IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-59184-5.html
   My bibliography  Save this article

ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27

Author

Listed:
  • Yong Wang

    (UT Southwestern Medical Center)

  • Yanan Wang

    (UT Southwestern Medical Center)

  • Lei Bao

    (UT Southwestern Medical Center)

  • Goncalo Vale

    (UT Southwestern Medical Center
    UT Southwestern Medical Center)

  • Jeffrey G. McDonald

    (UT Southwestern Medical Center
    UT Southwestern Medical Center)

  • Yisheng Fang

    (UT Southwestern Medical Center)

  • Yan Peng

    (UT Southwestern Medical Center)

  • Ashwani Kumar

    (UT Southwestern Medical Center)

  • Chao Xing

    (UT Southwestern Medical Center
    UT Southwestern Medical Center)

  • Fara Brasó-Maristany

    (August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
    Hospital Clínic of Barcelona
    S.L.)

  • Aleix Prat

    (August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
    Hospital Clínic of Barcelona
    S.L.
    University of Barcelona)

  • Carlos L. Arteaga

    (UT Southwestern Medical Center)

  • Yingfei Wang

    (UT Southwestern Medical Center
    UT Southwestern Medical Center
    UT Southwestern Medical Center
    UT Southwestern Medical Center)

  • Weibo Luo

    (UT Southwestern Medical Center
    UT Southwestern Medical Center
    UT Southwestern Medical Center)

Abstract

Anti-HER2 antibodies are effective but often lead to resistance in patients with HER2+ breast cancer. Here, we report an epigenetic crosstalk with aberrant glycerophospholipid metabolism and inflammation as a key resistance mechanism of anti-HER2 therapies in HER2+ breast cancer. Histone reader ZMYND8 specifically confers resistance to cancer cells against trastuzumab and/or pertuzumab. Mechanistically, ZMYND8 enhances cPLA2α expression in resistant tumor cells through inducing c-Myc. cPLA2α inactivates phosphatidylcholine-specific phospholipase C to inhibit phosphatidylcholine breakdown into diacylglycerol, which diminishes protein kinase C activity leading to interleukin-27 secretion. Supplementation with interleukin-27 protein counteracts cPLA2α loss to reinforce trastuzumab resistance in HER2+ tumor cells and patient-derived organoids. Upregulation of ZMYND8, c-Myc, cPLA2α, and IL-27 is prevalent in HER2+ breast cancer patients following HER2-targeted therapies. Targeting c-Myc or cPLA2α effectively overcomes anti-HER2 therapy resistance in patient-derived xenografts. Collectively, this study uncovers a druggable signaling cascade that drives resistance to HER2-targeted therapies in HER2+ breast cancer.

Suggested Citation

  • Yong Wang & Yanan Wang & Lei Bao & Goncalo Vale & Jeffrey G. McDonald & Yisheng Fang & Yan Peng & Ashwani Kumar & Chao Xing & Fara Brasó-Maristany & Aleix Prat & Carlos L. Arteaga & Yingfei Wang & Wei, 2025. "ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27," Nature Communications, Nature, vol. 16(1), pages 1-19, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59184-5
    DOI: 10.1038/s41467-025-59184-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-59184-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-59184-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59184-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.